The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis
Open accessAbstract
Background & aims It is unclear how long pancreatic ductal adenocarcinomas (PDACs) are present before diagnosis. Patients with PDAC usually develop hyperglycemia and diabetes before the tumor is identified. If early invasive PDACs are associated with hyperglycemia, the duration of hyperglycemia should associate with the time that they have had the tumor.Methods We collected data on patients with PDACs from medical databases in Olmsted County, Minnesota, from 2000 through 2015 and from the Mayo Clinic's tumor registry from January 1, 1976, through January 1, 2017. We compared glycemic profiles of patients with PDAC (cases) compared with patients without cancer, matched for age and sex (controls). We analyzed temporal fasting blood glucose (FBG) profiles collected for 60 months before patients received a PDAC diagnosis (index date) (n = 219) (cohort A), FBG profiles of patients with resected PDAC (n = 526) stratified by tumor volume and grade (cohort B), and temporal FBG profiles of patients with resected PDACs from whom long-term FBG data were available (n = 103) (cohort C). The primary outcome was to estimate duration of presence of invasive PDAC before its diagnosis based on hyperglycemia, defined as significantly higher (P < .05) FBG levels in cases compared with controls.Results In cohort A, the mean FBG did not differ significantly between cases and controls 36 months before the index date. Hyperglycemia was first noted 36 to 30 months before PDAC diagnosis in all cases, those with or without diabetes at baseline and those with or without resection at diagnosis. FBG level increased until diagnosis of PDAC. In cohort B, the mean FBG did not differ significantly in controls vs cases with PDACs below 1.0 mL. The smallest tumor volume associated with hyperglycemia was 1.1 to 2.0 mL; FBG level increased with tumor volume. FBG varied with tumor grade: well- or moderately differentiated tumors (5.8 mL) produced the same FBG levels as smaller, poorly differentiated tumors (1.5 mL) (P < .001). In cohort C, the duration of prediagnostic hyperglycemia for cases with large-, medium-, or small-volume PDACs was 36 to 24, 24 to 12, and 12 to 0 months, respectively. PDAC resection resolved hyperglycemia, regardless of tumor location.Conclusions In a case-control study of patients with PDAC from 2 databases, we associated FBG level with time to PDAC diagnosis and tumor volume and grade. Patients are hyperglycemic for a mean period of 36 to 30 months before PDAC diagnosis; this information might be incorporated into strategies for early detection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators
Riall, T. S., Yeo, C. J., Cameron, J. L., Koniaris, L. G., Kaushal, S., Abrams, R. A., Sauter, P. K., Coleman, J., Hruban, R. H., & Lillemoe, K. D. (2000) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(00)80105-5 · Cited by 1,482
History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Rocca, W., Yawn, B. P., Sauver, J. S. S., Grossardt, B., & Melton, L. (2012) · Mayo Clinic proceedings · doi:10.1016/j.mayocp.2012.08.012 · Cited by 775
Prevalence and Clinical Profile of Pancreatic Cancer–Associated Diabetes Mellitus
Pannala, R., Leirness, J. B., Bamlet, W. R., Basu, A., Petersen, G. M., & Chari, S. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.039 · Cited by 621
Self-citationProbability of Pancreatic Cancer Following Diabetes: A Population-Based Study
Chari, S. T., Leibson, C. L., Rabe, K. G., Ransom, J., de Andrade, M., & Petersen, G. M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.05.007 · Cited by 603
New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer
Pannala, R., Basu, A., Petersen, G. M., & Chari, S. T. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70337-1 · Cited by 577
Akakura, N., Kobayashi, M., Horiuchi, I., Suzuki, A., Wang, J., Chen, J., Niizeki, H., Ki, K., Hosokawa, M., & Asaka, M. (2001) · PubMed · Cited by 340
Flagged first, then by citations
1 of the 29 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–205 of 205
The use of blood test trends in cancer detection: a scoping review
Zhu, S., Smith, C. F., Collins, K. K., Ziyenge, S. E., Murphy, J., Hunt, I. D. V., Brubert, Z., Roberts, N., Morris, E. J. A., Hobbs, R., et al. (2026) · Diagnostic and Prognostic Research · doi:10.1186/s41512-026-00236-9
Masamune, A., Tanaka, Y., Tanaka, Y., Takikawa, T., Sekino, Y., Matsumoto, R., Asai, Y., Katagiri, H., Ueki, K., & Kikuta, K. (2026) · Cancers · doi:10.3390/cancers18182995
Quantifying annotation-stratified pleiotropy and co-polygenicity between complex traits
Qu, J., Zhao, T., Lin, T., Li, A., Liu, S., Chauquet, S., Visscher, P. M., Wray, N. R., Yengo, L., Zeng, J., et al. (2026) · World Congress on Genetics Applied to Livestock Production (WCGALP) · doi:10.31274/wcgalp.24241
Zhu, H., Fan, H., Yang, W., Gao, S., Chang, J., Zong, G., Zhuang, Y., Abudukeranmu, A., Jia, X., Zhu, Y., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-339722
Camacho-Flores, L. M., Alvarez, A., Vazquez, R. B., Benet, P., García, C. B. A., & del Rio, M. M. (2026) · Cureus · doi:10.7759/cureus.117696
Metadata
- Authors
- Sharma, A., Smyrk, T. C., Levy, M. J., Topazian, M. A., & Chari, S. T.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Chari, Suresh T.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 155
- Issue
- 2
- Pages
- 490-500.e2
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC6067966
- OpenAlex
- W2802707526
- Cited by
- 204
- References
- 29
- Citations by year
- 2026: 17 · 2025: 21 · 2024: 25 · 2023: 22 · 2022: 33 · 2021: 32 · 2020: 31 · 2019: 17 · 2018: 6
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Gastroenterology (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy
- National Institute on Aging (R01AG034676)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK108288)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic ductal adenocarcinoma, fasting blood glucose, diabetes mellitus, tumor progression, tumor volume, tumor grade, time to diagnosis, glycemic markers, cancer screening, Olmsted County, Minnesota, resected pancreatic cancer, tumor differentiation
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Fasting, Female, Humans, Hyperglycemia, Male, Middle Aged, Minnesota, Pancreas, Pancreatic Neoplasms, Time Factors, Case-Control Studies, Disease Progression, Carcinoma, Pancreatic Ductal, Tumor Burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
